Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Stimulator of interferon genes–TANK-binding kinase 1 (STING–TBK1) protein–protein interface is a critical regulatory junction in the cGAS-STING signaling pathway, which detects cytosolic DNA as a signal of infection or cellular damage (UniProt Q86WV6, Q9UHD2). Upon activation by cyclic GMP-AMP (cGAMP), STING dimers undergo a conformational change and translocate from the endoplasmic reticulum to the Golgi apparatus, where they recruit TBK1 via a conserved pLxIS motif located in the STING C-terminal tail (Liu et al., 2015, Science). This interaction facilitates the trans-autophosphorylation of TBK1 and the subsequent phosphorylation of the transcription factor IRF3, which is essential for the induction of Type I interferons and other pro-inflammatory cytokines (Zhang et al., 2019, Nature). In oncology, pharmacological agonists are used to stabilize or enhance this interface to promote anti-tumor immunity, while in autoinflammatory conditions like SAVI, small molecule inhibitors or disruptors of this interface are being developed to prevent constitutive immune activation. The interface represents a high-precision target for modulating innate immunity, as it sits downstream of DNA sensing but upstream of broad transcriptional responses.
Modulation of the recruitment and activation of TBK1 by STING to either enhance or suppress downstream IRF3 phosphorylation and Type I interferon gene expression.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stimulator of interferon genes–TANK-binding kinase 1 protein–protein interface (STING–TBK1 interface).